Aurion Biotech
Aurion Biotech develops regenerative cell therapies for the treatment of blindness and vision loss, with a lead program focused on corneal endothelial cell therapy for patients with corneal endothelial disease. Its therapies aim to restore vision by replacing lost or dysfunctional endothelial cells using human donor cells, providing a less invasive alternative to traditional corneal transplantation. The organization’s mission is to expand global access to advanced ophthalmic care and address significant unmet needs in treating blindness.
Facts
- HQ
- Seattle
- Sectors
- Biotechnology
- Founded
- 2022
- Employees
- 116
- Stage
- Clinical stage
- Members see funding amounts. .
Is this your organization? Claim it
Members see Aurion Biotech's funding rounds, amounts and investors.
Seattle Flow is free for everyone.
- Claim and edit your profile
- Get alerts about you, your company, and anything else you care about
- Access the most comprehensive investor list in Seattle
- Join the conversation on news, podcasts, and events
People
-
Arnaud Lacoste Executive, Executive Officer, CEO and Chief Scientific Officer
-
Greg Kunst Executive, Executive Officer, Director, CEO